Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis
Authors:
- Paul GressenbergerPGPaul Gressenberger
- Philipp JudPJPhilipp Jud
- Gabor KovacsGKGabor Kovacs
- Sonja KreuzerSKSonja Kreuzer
- Hans-Peter BrezinsekHBHans-Peter Brezinsek
- Katharina GuetlKGKatharina Guetl
- Viktoria MusterVMViktoria Muster
- Ewald KolesnikEKEwald Kolesnik
- Albrecht SchmidtASAlbrecht Schmidt
- Balazs OdlerBOBalazs Odler
- Gabriel AdelsmayrGAGabriel Adelsmayr
- Peter NeumeisterPNPeter Neumeister
Open Access
- 25 June 2021
- journal article
- case report
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (7) , 600
Abstract
Systemic sclerosis (SSc) is an intractable autoimmune disease characterized by vasculopathy and organ fibrosis. Autologous hematopoietic stem cell transplantation (AHSCT) should be considered for the treatment of selected patients with rapid progressive SSc at high risk of organ failure. It, however, remains elusive whether immunosuppressive therapies such as rituximab (RTX) are still necessary for such patients after AHSCT, especially in those with bad outcomes. In the present report, a 43-year-old man with diffuse cutaneous SSc received AHSCT. Despite AHSCT, SSc further progressed with progressive symptomatic heart failure with newly developed concomitant mitral and tricuspid valve insufficiency, thus the patient started on RTX 8 months after AHSCT. Shortly after initiation of RTX, clinical symptoms and organ functions ameliorated subsequently. Heart valve regurgitations were reversible after initiation of RTX treatment. Currently, the patient remains in a stable condition with significant improvement of clinical symptoms and organ functions. Reporting about therapies after AHSCT in SSc is a very important issue, as randomized controlled trials are lacking, and therefore this report adds to evidence that RTX can be considered as a treatment option in patients with SSc that do not respond to AHSCT.Keywords
This publication has 17 references indexed in Scilit:
- Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort studyAnnals of the Rheumatic Diseases, 2019
- Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic SclerosisFrontiers in Immunology, 2018
- Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patientsBlood Advances, 2018
- Myeloablative Autologous Stem-Cell Transplantation for Severe SclerodermaNew England Journal of Medicine, 2018
- Update of EULAR recommendations for the treatment of systemic sclerosisAnnals of the Rheumatic Diseases, 2017
- Haematopoietic stem cell transplantation for autoimmune diseasesNature Reviews Rheumatology, 2017
- Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patientsJournal of Hematology & Oncology, 2017
- Dosage of rituximab in systemic sclerosis: 2-year results of five casesClinical and Experimental Dermatology, 2014
- Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimenScandinavian Journal of Rheumatology, 2013
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals of the Rheumatic Diseases, 2010